DK2737071T3 - IMPROVED BACULOVIRUS EXPRESSION SYSTEMS - Google Patents

IMPROVED BACULOVIRUS EXPRESSION SYSTEMS Download PDF

Info

Publication number: DK2737071T3
Authority: DK; Denmark
Prior art keywords: baculovirus; recombinant; genome; gene; raav
Prior art date: 2011-07-27

Application number

DK12745446.0T

Other languages

Danish (da)

English (en)

Inventor

Lionel Galibert

Otto-Wilhelm Merten

Oers Monique Van

Christel Riviere

Original Assignee

Genethon

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-27

Filing date

2012-07-27

Publication date

2017-05-08

2012-07-27 Application filed by Genethon filed Critical Genethon

2017-05-08 Application granted granted Critical

2017-05-08 Publication of DK2737071T3 publication Critical patent/DK2737071T3/en

Links

241000701447 unidentified baculovirus Species 0.000 title claims description 136
230000014509 gene expression Effects 0.000 title description 28
108090000623 proteins and genes Proteins 0.000 claims description 60
210000004027 cell Anatomy 0.000 claims description 50
101710181863 Structural DNA-binding protein p10 Proteins 0.000 claims description 38
101710086987 X protein Proteins 0.000 claims description 38
238000004519 manufacturing process Methods 0.000 claims description 37
102100038982 Exosome complex component RRP40 Human genes 0.000 claims description 30
239000002245 particle Substances 0.000 claims description 22
108010084457 Cathepsins Proteins 0.000 claims description 21
108010022172 Chitinases Proteins 0.000 claims description 21
102000012286 Chitinases Human genes 0.000 claims description 20
238000000034 method Methods 0.000 claims description 17
239000013598 vector Substances 0.000 claims description 17
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 14
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 14
241000700605 Viruses Species 0.000 claims description 11
108020004707 nucleic acids Proteins 0.000 claims description 8
102000039446 nucleic acids Human genes 0.000 claims description 8
150000007523 nucleic acids Chemical class 0.000 claims description 8
238000012258 culturing Methods 0.000 claims description 6
239000013607 AAV vector Substances 0.000 claims description 4
210000001236 prokaryotic cell Anatomy 0.000 claims description 4
241000702421 Dependoparvovirus Species 0.000 description 20
238000012217 deletion Methods 0.000 description 19
108020004414 DNA Proteins 0.000 description 18
230000037430 deletion Effects 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 17
102000005600 Cathepsins Human genes 0.000 description 16
241000238631 Hexapoda Species 0.000 description 16
101000585179 Rattus norvegicus Spermatid perinuclear RNA-binding protein Proteins 0.000 description 16
101710072850 Poxin Proteins 0.000 description 15
101710142282 Protein P26 Proteins 0.000 description 15
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 13
239000003550 marker Substances 0.000 description 13
210000003205 muscle Anatomy 0.000 description 11
230000002779 inactivation Effects 0.000 description 9
230000006798 recombination Effects 0.000 description 9
238000005215 recombination Methods 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
230000000694 effects Effects 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
239000013608 rAAV vector Substances 0.000 description 8
239000013603 viral vector Substances 0.000 description 8
230000003612 virological effect Effects 0.000 description 7
238000001262 western blot Methods 0.000 description 7
241000588724 Escherichia coli Species 0.000 description 6
102100032106 Transmembrane emp24 domain-containing protein 3 Human genes 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000011002 quantification Methods 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
241000702423 Adeno-associated virus - 2 Species 0.000 description 4
241000255789 Bombyx mori Species 0.000 description 4
108010051219 Cre recombinase Proteins 0.000 description 4
238000012224 gene deletion Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000017105 transposition Effects 0.000 description 4
101150044789 Cap gene Proteins 0.000 description 3
101710182846 Polyhedrin Proteins 0.000 description 3
241000255993 Trichoplusia ni Species 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000013320 baculovirus expression vector system Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000008034 disappearance Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
101150003612 pfo gene Proteins 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000004448 titration Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
241001164825 Adeno-associated virus - 8 Species 0.000 description 2
241001203868 Autographa californica Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000012521 purified sample Substances 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000012795 verification Methods 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
238000013343 AVB chromatography Methods 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
102000016579 Alpha-sarcoglycan Human genes 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010002947 Connectin Proteins 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000186226 Corynebacterium glutamicum Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241000951956 Galleria mellonella MNPV Species 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
241001147381 Helicoverpa armigera Species 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
101001071515 Homo sapiens Gastrin-releasing peptide Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
201000003533 Leber congenital amaurosis Diseases 0.000 description 1
201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
241001599018 Melanogaster Species 0.000 description 1
108700011259 MicroRNAs Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101100273112 Pseudomonas aeruginosa cap8 gene Proteins 0.000 description 1
102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108010083379 Sarcoglycans Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
241000256247 Spodoptera exigua Species 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
241000427729 Vasum Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000007825 histological assay Methods 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000003331 infrared imaging Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000002679 microRNA Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
238000010606 normalization Methods 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
108010031345 placental alkaline phosphatase Proteins 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
239000013647 rAAV8 vector Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
101150066583 rep gene Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002795 scorpion venom Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14051—Methods of production or purification of viral material
- C12N2710/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Plant Pathology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK12745446.0T 2011-07-27 2012-07-27 IMPROVED BACULOVIRUS EXPRESSION SYSTEMS DK2737071T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161512142P	2011-07-27	2011-07-27
PCT/EP2012/064843 WO2013014294A2 (en)	2011-07-27	2012-07-27	Improved baculovirus expression systems

Publications (1)

Publication Number	Publication Date
DK2737071T3 true DK2737071T3 (en)	2017-05-08

Family

ID=46640007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12745446.0T DK2737071T3 (en)	2011-07-27	2012-07-27	IMPROVED BACULOVIRUS EXPRESSION SYSTEMS

Country Status (10)

Country	Link
US (1)	US10480010B2 (2)
EP (1)	EP2737071B1 (2)
JP (1)	JP6122430B2 (2)
CN (1)	CN103748229A (2)
BR (1)	BR112014001863A2 (2)
CA (1)	CA2842392C (2)
DK (1)	DK2737071T3 (2)
ES (1)	ES2623780T3 (2)
IN (1)	IN2014CN00688A (2)
WO (1)	WO2013014294A2 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015191508A1 (en)	2014-06-09	2015-12-17	Voyager Therapeutics, Inc.	Chimeric capsids
SG11201703148TA (en)	2014-11-05	2017-05-30	Voyager Therapeutics Inc	Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh)	2014-11-14	2025-04-25	沃雅戈治疗公司	调节性多核苷酸
CA3193811A1 (en)	2014-11-14	2016-05-19	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (als)
HK1245326A1 (zh) *	2014-12-12	2018-08-24	Voyager Therapeutics, Inc.	用於生产scaav的组合物和方法
EP3448874A4 (en)	2016-04-29	2020-04-22	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en)	2016-04-29	2020-05-27	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
CA3024449A1 (en)	2016-05-18	2017-11-23	Voyager Therapeutics, Inc.	Compositions and methods of treating huntington's disease
CA3024448C (en)	2016-05-18	2025-09-09	Voyager Therapeutics, Inc.	MODULATING POLYNUCLEOTIDES
WO2018044933A1 (en)	2016-08-30	2018-03-08	The Regents Of The University Of California	Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3618839A4 (en)	2017-05-05	2021-06-09	Voyager Therapeutics, Inc.	COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja)	2017-05-05	2020-06-25	ボイジャーセラピューティクスインコーポレイテッドＶｏｙａｇｅｒＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ハンチントン病治療組成物および方法
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja)	2017-07-17	2023-02-28	ボイジャーセラピューティクスインコーポレイテッド	軌道アレイガイドシステム
JP7221275B2 (ja)	2017-08-03	2023-02-13	ボイジャーセラピューティクスインコーポレイテッド	Ａａｖを送達するための組成物および方法
US20200263199A1 (en)	2017-09-29	2020-08-20	Voyager Therapeutics, Inc.	Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2019079242A1 (en)	2017-10-16	2019-04-25	Voyager Therapeutics, Inc.	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh)	2017-10-16	2024-04-01	美商航海家醫療公司	肌萎縮性脊髓側索硬化症(als)之治療
SG11202011296VA (en)	2018-05-15	2020-12-30	Voyager Therapeutics Inc	Compositions and methods for the treatment of parkinson's disease
US12281321B2 (en)	2018-09-28	2025-04-22	Voyager Therapeutics, Inc.	Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072844A1 (en) *	2018-10-05	2020-04-09	Voyager Therapeutics, Inc.	Engineered nucleic acid constructs encoding aav production proteins
CA3116701A1 (en) *	2018-10-15	2020-04-23	Voyager Therapeutics, Inc.	Expression vectors for large-scale production of raav in the baculovirus/sf9 system
CN109609552B (zh) *	2018-12-28	2020-04-14	中国科学院武汉物理与数学研究所	重组腺相关病毒的制备方法、系统及重组杆粒
US11718834B2 (en)	2019-02-15	2023-08-08	Sangamo Therapeutics, Inc.	Compositions and methods for producing recombinant AAV
KR102272651B1 (ko) *	2019-03-28	2021-07-02	충북대학교 산학협력단	외래단백질의 발현량과 발현시간이 증대된 배큘로바이러스
US20200407696A1 (en) *	2019-06-26	2020-12-31	Haifeng Chen	Baculovirus expression system
WO2022079082A1 (en)	2020-10-15	2022-04-21	F. Hoffmann-La Roche Ag	Nucleic acid constructs for simultaneous gene activation
CN114317608B (zh) *	2020-12-28	2023-08-22	陕西杆粒生物科技有限公司	一种基因敲除型杆状病毒表达载体
CN117716044A (zh) *	2021-07-28	2024-03-15	生物马林药物股份有限公司	大规模腺相关病毒生产系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE58011B1 (en)	1983-05-27	1993-06-16	Texas A & M Univ Sys	Method for producing a recombinant baculovirus expression vector
US4745051A (en)	1983-05-27	1988-05-17	The Texas A&M University System	Method for producing a recombinant baculovirus expression vector
ZA848495B (en)	1984-01-31	1985-09-25	Idaho Res Found	Production of polypeptides in insect cells
FR2664905B1 (fr) *	1990-07-18	1994-08-12	Agronomique Inst Nat Rech	Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
CN1205741A (zh) *	1995-12-22	1999-01-20	纳幕尔杜邦公司	重组杆状病毒的生产

2012
- 2012-07-27 EP EP12745446.0A patent/EP2737071B1/en not_active Not-in-force
- 2012-07-27 CA CA2842392A patent/CA2842392C/en not_active Expired - Fee Related
- 2012-07-27 CN CN201280037489.9A patent/CN103748229A/zh active Pending
- 2012-07-27 WO PCT/EP2012/064843 patent/WO2013014294A2/en not_active Ceased
- 2012-07-27 ES ES12745446.0T patent/ES2623780T3/es active Active
- 2012-07-27 BR BR112014001863A patent/BR112014001863A2/pt active Search and Examination
- 2012-07-27 JP JP2014522116A patent/JP6122430B2/ja active Active
- 2012-07-27 DK DK12745446.0T patent/DK2737071T3/en active
- 2012-07-27 US US14/234,949 patent/US10480010B2/en not_active Expired - Fee Related
- 2012-07-27 IN IN688CHN2014 patent/IN2014CN00688A/en unknown

Also Published As

Publication number	Publication date
CA2842392C (en)	2020-09-15
CN103748229A (zh)	2014-04-23
JP6122430B2 (ja)	2017-04-26
EP2737071A2 (en)	2014-06-04
JP2014522658A (ja)	2014-09-08
IN2014CN00688A (2)	2015-04-03
WO2013014294A2 (en)	2013-01-31
US10480010B2 (en)	2019-11-19
EP2737071B1 (en)	2017-03-15
US20140356904A1 (en)	2014-12-04
CA2842392A1 (en)	2013-01-31
ES2623780T3 (es)	2017-07-12
BR112014001863A2 (pt)	2017-02-21
WO2013014294A3 (en)	2013-04-04

Publication	Publication Date	Title
DK2737071T3 (en)	2017-05-08	IMPROVED BACULOVIRUS EXPRESSION SYSTEMS
US11414676B2 (en)	2022-08-16	AAV production in insect cells, methods and compositions therefor
US9115373B2 (en)	2015-08-25	Use of AAV replication machinery for improved protein production
US10767192B2 (en)	2020-09-08	Baculovirus system for the expression of a gene therapy vector
US10829784B2 (en)	2020-11-10	Method for preparing recombinant adeno-associated virus
US20200407696A1 (en)	2020-12-31	Baculovirus expression system
Bai et al.	2019	Major capsid protein of Autographa californica multiple nucleopolyhedrovirus contributes to the promoter activity of the very late viral genes
US20250297278A1 (en)	2025-09-25	Insect cell-produced high potency AAV vectors with CNS-tropism
US12416019B2 (en)	2025-09-16	Expression cassette containing overlapping open reading frames and application
WO2025165781A1 (en)	2025-08-07	Stable recombinant virus and methods of use thereof
Aurelien et al.	2020	Advantages of homologous recombination-over transposition-based systems to generate recombinant baculovirus for AAV vector production
CN118956966A (zh)	2024-11-15	核酸分子、包含其的重组杆状病毒及其应用